Drugs / lopinavir-ritonavir
lopinavir-ritonavir
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT04499677 | Sep 2020 → Dec 2021 | COVID-19 | University College, London | Completed | Missed primary |
| Phase 2 | NCT01231685 | Dec 2011 → Mar 2016 | HIV infectious disease, fibrotic liver disease, hepatitis C virus infection | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04354428 | Apr → Nov 2020 | COVID-19 | University of Washington | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01061151 | Mar 2011 → Sep 2016 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Mixed |
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT02369965 Background | Feb 2014 → Apr 2018 | AIDS | Frontier Biotechnologies Inc. | Completed | Met primary |
| Phase 3 | NCT00427297 Comparator | Sep 2007 → May 2009 | HIV infectious disease | University of Washington | Terminated | No outcome recorded |
| — | NCT00428116 Comparator | Sep 2007 → Jul 2013 | HIV infectious disease | University of Washington | Terminated | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-02-27 | AbbVie | AbbVie Statement on Coronavirus and lopinavir/ritonavir abbvie.com ↗ |
| 2006-08-17 | Vertex Pharmaceuticals Incorporated | Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra Presented at IAC 2006 and Published in The Lancet vrtx.com ↗ |
| 2006-05-16 | Vertex Pharmaceuticals Incorporated | GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV vrtx.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lopinavir/ritonavir | “Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.” PMID 36260627 ↗ Oct 20227“Second line regimen - ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir (Kaletra))” NCT00428116 ↗ “ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)” NCT00427297 ↗ “Lopinavir-ritonavir” NCT04354428 ↗ “Lopinavir-ritonavir” NCT01231685 ↗ |
| Known as | kaletra | “Second line regimen - ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir (Kaletra))” NCT00428116 ↗2“* ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir (kaletra))” NCT00427297 ↗ “Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]” NCT04354428 ↗ |
| Known as | LPV-RTV | “Lopinavir-ritonavir (LPV-RTV)” NCT01061151 ↗ |
| Known as | LPV/r | “Second line regimen - ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir (Kaletra))” NCT00428116 ↗2“ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)” NCT00427297 ↗ “lopinavir-ritonavir (LPV/r)” NCT04354428 ↗ |
| Route | Oral | “administered orally twice daily” NCT02369965 ↗ |